Kiora Pharmaceuticals Ownership
KPRX Stock | USD 3.37 0.06 1.81% |
Shares in Circulation | First Issued 2013-03-31 | Previous Quarter 4.2 M | Current Value 4.2 M | Avarage Shares Outstanding 1.7 M | Quarterly Volatility 5.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Kiora |
Kiora Stock Ownership Analysis
About 48.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.34. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Kiora Pharmaceuticals recorded earning per share (EPS) of 16.53. The entity last dividend was issued on the 30th of August 2019. The firm had 1:9 split on the 11th of June 2024. Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah. Kiora Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. To find out more about Kiora Pharmaceuticals contact Brian Strem at 858 224 9600 or learn more at https://www.kiorapharma.com.Besides selling stocks to institutional investors, Kiora Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Kiora Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Kiora Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Kiora Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Kiora Pharmaceuticals Insider Trades History
Roughly 2.0% of Kiora Pharmaceuticals are currently held by insiders. Unlike Kiora Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Kiora Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Kiora Pharmaceuticals' insider trades
Kiora Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Kiora Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kiora Pharmaceuticals backward and forwards among themselves. Kiora Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Kiora Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Bank Of America Corp | 2024-06-30 | 20.0 | U.s. Bancorp | 2024-06-30 | 8.0 | Activest Wealth Management | 2024-06-30 | 3.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.0 | Jpmorgan Chase & Co | 2024-06-30 | 1.0 | Captrust Financial Advisors | 2024-06-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Tower Research Capital Llc | 2024-06-30 | 0.0 | Two Sigma Investments Llc | 2024-06-30 | 0.0 | Aigh Capital Management, Llc | 2024-09-30 | 255.6 K | Nantahala Capital Management, Llc | 2024-09-30 | 211.1 K |
Kiora Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kiora Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kiora Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kiora Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kiora Pharmaceuticals Outstanding Bonds
Kiora Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Kiora Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Kiora bonds can be classified according to their maturity, which is the date when Kiora Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Boeing Co 2196 Corp BondUS097023DG73 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
KIRBY P 42 Corp BondUS497266AC03 | View |
Kiora Pharmaceuticals Corporate Filings
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 13th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 8th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 29th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Kiora Stock Analysis
When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.